A Cost Analysis of the Prevention of End-stage Renal Disease

Abstract

A cost analysis was used to evaluate three possible immunoglobulin (IgG) treatment protocols for end-stage renal disease due to IgA nephropathy. The perspective chosen for the cost analysis was that of the health-care delivery system. The baseline strategy was the absence of IgG treatment, and alternative strategies corresponded to three protocols presently on trial: all three included a high initial dose of intravenous IgG. Protocol 1 followed with intramuscular IgG injections only, protocol 2 with intramuscular plus intravenous injections, and protocol 3 with intravenous injections only. The costs of treatment included the costs of immunoglobulins, outpatient hospital costs, and the costs of tests; the savings (costs averted) resulted from kidney dialysis averted. The bottom line for the health-care system is a net savings of $233,000, $213,000, or $83,000, depending on the protocol chosen. The computation of costs did not value physical and psychological health benefits. Thus, any subjective benefit, such as im proved comfort, or objective benefit, such as longer life expectancy, would be an im provement over the results presented here. Key words: cost analysis; end-stage renal disease; treatment protocols. (Med Decis Making 1996;16:326-334)

Get full access to this article

View all access options for this article.

References

Berger J. IgA glomerular deposits in renal disease. Transplant Proc 1969;1 939-44.

D'Amico G.

The commonest glomerulonephritis in the world. IgA nephropathy

Q J Med 1987;64.709-27

Emancipator S. , Gallo G. , Lamm M.

IgA nephropathy perspectives on pathogenesis and classification

Clin Nephrol 1985,24 161-79

Lee K. , Vijaykumar R. , Wilbur F. , et al IgA nephropathy morphologic predictors of progressive renal disease Hum Pathol. 1982,13.314-22

Schena P.

A retrospective analysis of the natural history of primary IgA nephropathy worldwide

Am J Med 1980,89 209 -15.

Magil A. , Ballon H.

IgA nephropathy evaluation of prognostic factors in patients with moderate disease

Nephron. 1987,47 246-52

Rostoker G. , Devaux-Belghiti D. , Terzidis H. , et al. High-dose immunoglobulin therapy for severe IgA nephropathy and Henoch-Schoenlein purpura. Ann Intern Med. 1994,120 476-84.

Drummond M. , Stoddart G. , Torrance G. Methods for economic evaluation of health care programmes. Oxford, U.K.. Oxford University Press, 1989.

Weinstein M. Principles of cost-effective resource allocation in health care organizations. Int J Technol Assess Health Care 1990,6.93-106.

10.

Krahn M. , Gafni A. Discounting in the economic evaluation of health care interventions . Med Care 1993;31 403-18.

11.

Martens L. , Van Doorslaer E.

DEALing with discounting an application to the cost-effectiveness of intracoronary thrombolysis with streptokinase

Int J Technol Assess Health Care 1990,6 139 -46.

12.

Beck R. , Kassirer J. , Pauker S. A convenient approximation of life expectancy (the "DEALE") Use in medical decision making. Am J Med 1982,73 889-99.

13.

Beck R. , Kassirer J. , Pauker S. A convenient approximation of life expectancy (the "DEALE"). Validation of the method. Am J Med. 1982,73 883-8.

14.

Stalpers L. , Van Gasteren H. , Van Daal W.

DEALE-ing with life expectancy and mortality rates

Med Decis Making 1989;9 150-2

15.

Iversen GR Bayesian statistical inference Sage University paper series on quantitative applications in the social sciences, 07-043. Beverly Hills, CA, and London, U K., 1984, pp 37, 51

16.

Drummond M. Cost-effectiveness guidelines for the reimbursement of pharmaceuticals is economic evaluation ready for its enhanced status? Health Econ. 1992,1 85-92.